Holen Sie sich die Stockscreener-App
80.94
0.26%
0.16
Schlusskurs vom Vortag:
$80.78
Offen:
$81.5
24-Stunden-Volumen:
1.14M
Relative Volume:
0.67
Marktkapitalisierung:
$9.60B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$348.84M
KGV:
29.11
EPS:
2.7805
Netto-Cashflow:
$667.65M
1W Leistung:
+3.47%
1M Leistung:
+13.22%
6M Leistung:
+7.82%
1J Leistung:
+49.37%
1-Tages-Spanne:
$80.61
$82.26
1-Wochen-Bereich:
$75.71
$82.26
52-Wochen-Spanne:
$54.15
$82.26
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
80.94 | 9.58B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
522.00 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.13 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.99 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Herabstufung | Goldman | Neutral → Sell |
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme's Q4 earnings miss, higher royalties drive Y/Y revenues - MSN
Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued - Sahm
Price to sales forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
Halozyme Therapeutics Operating Chief Caudill to Exit - Moomoo
Halozyme stock falls as chief operating officer departs By Investing.com - Investing.com Nigeria
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
Halozyme stock falls as chief operating officer departs - Investing.com
Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting - Stock Titan
Halozyme (NASDAQ: HALO) CFO awarded large option and RSU package - Stock Titan
Halozyme (HALO) director sells 1,625 shares in 10b5-1 trades - Stock Titan
Halozyme Therapeutics (HALO) COO Cortney Caudill to depart in management reshuffle - Stock Titan
Halozyme Therapeutics, Inc. Announces Departure of Cortney Caudill as Senior Vice President, Chief Operating Officer - marketscreener.com
Is Halozyme (HALO) Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative? - Sahm
Halozyme names David Ramsay as president drug delivery - Investing.com UK
Halozyme names David Ramsay as president drug delivery By Investing.com - Investing.com South Africa
Halozyme director Mahesh Krishnan sells $547,800 in stock By Investing.com - Investing.com South Africa
Form 4 Halozyme Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia
Halozyme director Mahesh Krishnan sells $547,800 in stock - Investing.com UK
Halozyme (HALO) director exercises options, sells 7,304 shares under plan - Stock Titan
Press Release: Halozyme Appoints David Ramsay as President Drug Delivery - Moomoo
Small Cap Core Portfolio I's Halozyme Therapeutics Inc(HALO) Holding History - GuruFocus
[144] HALOZYME THERAPEUTICS, INC. SEC Filing - Stock Titan
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Price to sales forward of Halozyme Therapeutics, Inc. – FWB:RV7 - TradingView
Price to sales forward of Halozyme Therapeutics, Inc. – BMV:HALO - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (NASDAQ:HALO) - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (DUS:RV7) - TradingView
Halozyme Therapeutics Inc (HALO) Institutional Confidence - TradingKey
Halozyme Therapeutics, Inc. Actuals & Estimates (FWB:RV7) - TradingView
HALO Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
RV7 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView
Price to earnings forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection - GlobeNewswire Inc.
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Exploring a 22% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Halozyme Therapeutics Inc (HALO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
META_TITLE_QUOTE - Yahoo Finance
Did Expanding ENHANZE Partnerships and Cash Generation Just Shift Halozyme Therapeutics' (HALO) Investment Narrative? - Sahm
HALOZYME THERAPEUTICS INC (HALO) Stock Chart - ChartMill
Halozyme Therapeutics Inc (HALO) Valuation: PE, PB & Fair Value Analysis - TradingKey
What Halozyme Therapeutics (HALO)'s New ENHANZE Partner Data and Analyst Support Means For Shareholders - Sahm
Halozyme Therapeutics (HALO) Stock Could Be 18.8% Undervalued As Partner Growth Lifts Sentiment - Sahm
Halozyme Therapeutics Inc (HALO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Halozyme Therapeutics Inc (HALO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Halozyme Therapeutics Inc (HALO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Halozyme Therapeutics Inc (HALO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Halozyme Therapeutics Inc (HALO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Halozyme Therapeutics Inc-Aktie (HALO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Connaughton Bernadette | Director |
Jul 01 '26 |
Sale |
76.71 |
1,625 |
124,651 |
42,044 |
| Krishnan Mahesh | Director |
Jun 29 '26 |
Option Exercise |
38.46 |
7,304 |
280,912 |
21,766 |
| Krishnan Mahesh | Director |
Jun 29 '26 |
Sale |
75.00 |
7,304 |
547,800 |
14,462 |
1.21%
3.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):